Pfizer acquisition of cancer drug company could advance oncology research

Published Online: Aug 23,2016 Laurie Toich, Assistant Editor Pfizer recently announced its plans to acquire Medivation, a biopharmaceutical company that develops molecules for oncology. Recent health insurer mergers could have deterred the $14 billion deal, but Pfizer and Medivation’s boards of directors approved the merger, and expect that shares will increase immediately, according to a press release from Pfizer. “The proposed …